| DC10160 |
(1R,2S)-VU0155041 |
(1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial mGluR4 agonist with an EC50 of 2.35 μM. |
-VU0155041 .gif)
|
| DC11609 |
VU6010608 |
A potent, highly selective, CNS penetrant mGlu7 negative allosteric modulator with IC50 of 0.76 uM. |
|
| DC11895 |
Foliglurax hydrochloride |
A potent, selective, brain-penetrant and orally bioavailable mGluR4 positive allosteric modulator with EC50 of 79 nM. |
|
| DC11894 |
Foliglurax |
A potent, selective, brain-penetrant and orally bioavailable mGluR4 positive allosteric modulator with EC50 of 79 nM. |
|
| DC8087 |
ADX 47273
Featured
|
ADX-47273 is a novel, potent and selective metabotropic glutamate receptor 5 allosteric modulator with an EC50 of 170 nM. |
|
| DC10465 |
ADX-88178
Featured
|
ADX-88178 is a novel potent, selective, and brain-penetrant positive allosteric modulator of the mGlu4 receptor. |
|
| DC9937 |
BMT-145027 |
BMT-145027 is a potent mGluR5 PAM with no inherent mGluR5 agonist activity. |
|
| DC9508 |
CPPHA
Featured
|
CPPHA is a selective positive allosteric modulator of mGluR5 receptor. |
|
| DC7016 |
JNJ40411813
Featured
|
For the detailed information of JNJ40411813, the solubility of JNJ40411813 in water, the solubility of JNJ40411813 in DMSO, the solubility of JNJ40411813 in PBS buffer, the animal experiment (test) of JNJ40411813, the cell expriment (test) of JNJ40411813, the in vivo, in vitro and clinical trial test of JNJ40411813, the EC50, IC50,and Affinity of JNJ40411813, Please contact DC Chemicals.. |
|
| DC7843 |
JNJ 42153605
Featured
|
JNJ 42153605 is a positive allosteric modulator of the metabotropic glutamate 2 receptor. |
|
| DC11323 |
LY354740 |
LY354740 is an agonist of the group II metabotropic glutamate receptor (mGluR) subtypes mGluR2 and mGluR3 (Kis = 99 and 94 nM, respectively). |
|
| DC7192 |
LY-404039
Featured
|
LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor. |
|
| DC7681 |
Mavoglurant (AFQ 056)
Featured
|
Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome.It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). |
|
| DC9507 |
MTEP (hydrochloride) |
MTEP Hcl is a potent, selective and non-competitive mGlu5 antagonist with IC50 and Ki of 5 nM and 16 nM, respectively. |
|
| DC9752 |
PHCCC
Featured
|
PHCCC is a Group I metabotropic glutamate receptor antagonist (IC50 ~ 3 μM). |
|
| DC7721 |
RG7090（Basimglurant）
Featured
|
RG7090(CTEP Derivative,Basimglurant, RO4917523) is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5). |
|
| DC9074 |
Topiramate |
Topiramate is an anticonvulsant that antagonizes GluR5 receptors and acts as a positive allosteric modulator of GABA receptor-mediated currents. |
|
| DC9928 |
VU 0364770
Featured
|
VU 0364770 is a positive allosteric modulator(PAM) of mGlu4 with EC50 of 1.1 μM, exhibits insignificant activity at 68 other receptors, including other mGlu subtypes. |
|
| DC11121 |
VU0418506 |
VU0418506 (VU 0418506) is a potent and selective mGlu4 positive allosteric modulator (PAM) with EC50 of 68 nM (hmGlu4). |
|
| DC11437 |
VU0652957
Featured
|
VU0652957 (VU2957, Valiglurax) is a potent, selective mGlu4 positive allosteric modulator (PAM) with EC50 of 64.6 nM in calcium mobilization human mGlu4/Gqi5 assays; showes excellent pharmacokinetics across species (low CLps, %F > 35%), an acceptable CYP profile (>30 uM vs. 3A4, 2D6 and 2C9, 12.5 uM vs. 2C19 and 1.5 uM vs. 1A2), no CYP induction or timedependent inhibition and excellent metabolite coverage across species; also shows attractive predicted human PK parameters (CLps 5-9 mL/min/kg, Vds 1-2 L/kg and t1/2 2-4 hours). |
|
| DC10717 |
VU6005649
Featured
|
VU6005649 is a dual mGlu7/8 positive allosteric modulator with EC50s of 649 nM and 2.6 μM for mGlu7 and mGlu8, respectively. |
|
| DC28200 |
LY367385
Featured
|
LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with > 100 μM for mGlu5a. LY367385 has neuroprotective, anticonvulsant and antiepileptic effects. |
|
| DC28411 |
JNJ-46281222 |
JNJ-46281222 is an metabotropic glutamate (mGlu) 2-selective, highly potent PAM (positive allosteric modulator) with nanomolar affinity (Kd = 1.7 nM) and a high modulatory potency (pEC50 = 7.71). |
|
| DC28980 |
Biphenylindanone A
Featured
|
Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders. |
|
| DC28990 |
Decoglurant
Featured
|
Decoglurant (RO4995819) is a negative allosteric modulator of mGluR2 and mGluR3. Decoglurant is developed as an antidepressant. |
|
| DC40044 |
LY 541850 |
LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively. |
|
| DC40045 |
YM-298198 hydrochloride |
YM-298198 hydrochloride is a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1 (mGluR1). YM-298198 hydrochloride can be used for the research of neurological disorders. |
|
| DC40128 |
AZD 2066 hydrate |
AZD 2066 hydrate is a selective, orally active and brain-penetrant antagonist of mGluR5. AZD 2066 hydrate has antinociception effects. |
|
| DC40129 |
ADX71743 |
ADX71743 is a highly selective, noncompetitive and brain-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM). ADX71743 has anxiolytic-like activity. |
|
| DC40131 |
NPEC-caged-LY379268 |
NPEC-caged-LY379268 is a type II mGluR agonist. |
|
